{ "run": { "id": "cmnr0l2bq01k4p658meg8jxua", "region": "US", "assetId": "cmnr0l1so01jrp658j5kkj7qo", "ticker": "ABBV", "snapshotId": "cmnr0l28401jyp658d6azir51", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:06:13.380Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr0l28401jyp658d6azir51", "assetId": "cmnr0l1so01jrp658j5kkj7qo", "asOf": "2026-04-08T20:02:43.000Z", "snapshot": { "asOf": "2026-04-08T20:02:43.000Z", "quote": { "asOf": "2026-04-08T20:02:43.000Z", "open": null, "price": 211.59, "dayLow": 204.56, "volume": 3259406, "dayHigh": 212.21, "currency": "USD", "prevClose": 206.37, "week52Low": 164.39, "week52High": 244.81 }, "fundamentals": { "pe": 96.4092827004219, "beta": 0.356949392330546, "epsTTM": 2.37, "fcfTTM": 17774000000, "growth": { "epsYoy": -0.01249999999999992, "revenueYoy": 0.08566762523520431 }, "sector": "Pharmaceutical Preparations", "margins": { "net": 0.06909744931327665, "gross": 0.1972858077174624, "operating": 0.2464846304774362 }, "website": "http://abbvie.com", "industry": "Biopharmaceutical", "pegRatio": -77.1274261603378, "ebitdaTTM": 11507000000, "forwardPe": 15.6607265250171, "marketCap": 325061294916, "totalCash": 5229000000, "totalDebt": 67002000000, "debtEquity": -20.4899082568807, "quickRatio": 0.4122525352861004, "revenueTTM": 61160000000, "companyName": "AbbVie Inc.", "priceToBook": 4.45786205071081, "currentRatio": 0.6713483794959458, "dividendYield": 0.0292405610991284, "returnOnAssets": 0.03154673036727381, "returnOnEquity": -1.29235474006116, "analystOpinions": null, "businessSummary": "AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues. The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000.", "enterpriseValue": 465971810000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 57000, "sharesOutstanding": 1768169012, "enterpriseToEbitda": 40.49463891544277, "analystTargetMedian": null, "enterpriseToRevenue": 7.618898136036625, "operatingCashflowTTM": 19030000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:06:13.252Z" }, "results": [ { "id": "cmnr0l2bx01kbp6585c5bk0le", "runId": "cmnr0l2bq01k4p658meg8jxua", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:02:43.000Z\",\"ticker\":\"ABBV\",\"currency\":\"USD\",\"current_price\":211.59,\"target_price_6m\":220.0,\"target_price_12m\":228.0,\"recommendation\":\"BUY\",\"confidence\":0.65,\"thesis_bullets\":[\"Skyrizi and Rinvoq ramping strongly, offsetting Humira biosimilar erosion\",\"Forward P/E ~15.7x is attractive for diversified large-cap biopharma\",\"Robust FCF of ~$17.8B supports dividend growth and debt paydown\",\"Depressed TTM EPS reflects amortization/charges, not normalized earnings power\",\"Near-term risk from high leverage and ongoing Humira revenue decline\"],\"key_drivers\":[{\"driver\":\"Skyrizi/Rinvoq revenue ramp replacing Humira losses\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Humira biosimilar erosion trajectory\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Strong free cash flow generation enabling deleveraging\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Neuroscience and aesthetics portfolio stability (Botox, Vraylar)\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Pipeline catalysts across immunology and oncology\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"High debt load (~$67B) constraining financial flexibility\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Dividend yield ~2.9% attractive for income investors\",\"impact\":\"LOW\",\"direction\":\"POS\"},{\"driver\":\"Low beta (0.36) offering defensive characteristics\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Faster-than-expected Humira biosimilar penetration compresses revenue\",\"Pipeline trial failures or regulatory setbacks in key programs\",\"Pricing/reimbursement pressure from US drug policy reforms\",\"Elevated leverage limits M&A flexibility and increases interest expense\",\"Patent cliffs on Imbruvica and other key assets beyond Humira\"],\"assumptions\":{\"revenue_cagr_3y\":0.06,\"ebit_margin_target\":0.32,\"wacc\":0.085,\"terminal_multiple\":16.0},\"scenarios\":{\"bear\":{\"target_price\":185.0,\"prob\":0.2,\"notes\":\"Skyrizi/Rinvoq miss estimates; pricing reform headwinds compress multiples.\"},\"base\":{\"target_price\":228.0,\"prob\":0.55,\"notes\":\"Steady immunology franchise transition; EPS normalizes to ~$14+ supporting ~16x multiple.\"},\"bull\":{\"target_price\":265.0,\"prob\":0.25,\"notes\":\"Pipeline wins, margin expansion, and multiple re-rating toward premium pharma peers.\"}},\"method_notes\":\"Earnings-power valuation: normalized forward EPS ~$14.20 at 16x P/E = ~$227. FCF yield cross-check: $17.8B FCF / 8.5% WACC supports EV consistent with base target. TTM P/E of 96x reflects heavy amortization & non-cash charges, not operational weakness. 12M expected return ~7.8% (price) + ~2.9% dividend = ~10.7%, supporting BUY. Confidence moderate due to transition uncertainty. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:02:43.000Z", "model": "ai-equity-research-v1", "risks": [ "Faster-than-expected Humira biosimilar penetration compresses revenue", "Pipeline trial failures or regulatory setbacks in key programs", "Pricing/reimbursement pressure from US drug policy reforms", "Elevated leverage limits M&A flexibility and increases interest expense", "Patent cliffs on Imbruvica and other key assets beyond Humira" ], "ticker": "ABBV", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady immunology franchise transition; EPS normalizes to ~$14+ supporting ~16x multiple.", "target_price": 228 }, "bear": { "prob": 0.2, "notes": "Skyrizi/Rinvoq miss estimates; pricing reform headwinds compress multiples.", "target_price": 185 }, "bull": { "prob": 0.25, "notes": "Pipeline wins, margin expansion, and multiple re-rating toward premium pharma peers.", "target_price": 265 } }, "confidence": 0.65, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.06, "terminal_multiple": 16, "ebit_margin_target": 0.32 }, "key_drivers": [ { "driver": "Skyrizi/Rinvoq revenue ramp replacing Humira losses", "impact": "HIGH", "direction": "POS" }, { "driver": "Humira biosimilar erosion trajectory", "impact": "HIGH", "direction": "NEG" }, { "driver": "Strong free cash flow generation enabling deleveraging", "impact": "HIGH", "direction": "POS" }, { "driver": "Neuroscience and aesthetics portfolio stability (Botox, Vraylar)", "impact": "MED", "direction": "POS" }, { "driver": "Pipeline catalysts across immunology and oncology", "impact": "MED", "direction": "POS" }, { "driver": "High debt load (~$67B) constraining financial flexibility", "impact": "MED", "direction": "NEG" }, { "driver": "Dividend yield ~2.9% attractive for income investors", "impact": "LOW", "direction": "POS" }, { "driver": "Low beta (0.36) offering defensive characteristics", "impact": "LOW", "direction": "POS" } ], "method_notes": "Earnings-power valuation: normalized forward EPS ~$14.20 at 16x P/E = ~$227. FCF yield cross-check: $17.8B FCF / 8.5% WACC supports EV consistent with base target. TTM P/E of 96x reflects heavy amortization & non-cash charges, not operational weakness. 12M expected return ~7.8% (price) + ~2.9% dividend = ~10.7%, supporting BUY. Confidence moderate due to transition uncertainty. Not investment advice.", "current_price": 211.59, "recommendation": "BUY", "thesis_bullets": [ "Skyrizi and Rinvoq ramping strongly, offsetting Humira biosimilar erosion", "Forward P/E ~15.7x is attractive for diversified large-cap biopharma", "Robust FCF of ~$17.8B supports dividend growth and debt paydown", "Depressed TTM EPS reflects amortization/charges, not normalized earnings power", "Near-term risk from high leverage and ongoing Humira revenue decline" ], "target_price_6m": 220, "target_price_12m": 228 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 35406, "createdAt": "2026-04-09T05:06:13.380Z", "usage": { "inputTokens": 3597, "outputTokens": 1622, "costUsd": 0.058535 } }, { "id": "cmnr0l2bx01kep658vjezujna", "runId": "cmnr0l2bq01k4p658meg8jxua", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI_Equity_Research_Model_v1\",\n \"as_of\": \"2026-04-08T20:02:43.000Z\",\n \"ticker\": \"ABBV\",\n \"currency\": \"USD\",\n \"current_price\": 211.59,\n \"target_price_6m\": 212.0,\n \"target_price_12m\": 213.0,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\n \"Stable revenue growth from new immunology drugs.\",\n \"High debt load constrains financial flexibility.\",\n \"Dividend yield provides income support.\",\n \"Patent expirations pose ongoing risks.\",\n \"Valuation appears fair relative to peers.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Humira biosimilar competition\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Skyrizi and Rinvoq growth\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Cost management and margin stability\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Debt reduction efforts\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Regulatory approvals for new drugs\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Healthcare policy changes\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Currency fluctuations\", \"impact\": \"LOW\", \"direction\": \"NEG\" }\n ],\n \"risks\": [\n \"Patent cliffs leading to revenue decline\",\n \"Increased competition in immunology market\",\n \"Regulatory setbacks for pipeline drugs\",\n \"Economic downturn affecting drug sales\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.04,\n \"ebit_margin_target\": 0.25,\n \"wacc\": 0.08,\n \"terminal_multiple\": 15.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 180.0, \"prob\": 0.3, \"notes\": \"Slower drug adoption and multiple compression.\" },\n \"base\": { \"target_price\": 213.0, \"prob\": 0.5, \"notes\": \"Steady execution on current guidance.\" },\n \"bull\": { \"target_price\": 240.0, \"prob\": 0.2, \"notes\": \"Faster pipeline uptake and margin expansion.\" }\n },\n \"method_notes\": \"Used forward earnings estimate with PE multiple based on snapshot forward PE. Recommendation based on modest upside and mixed evidence. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:02:43.000Z", "model": "AI_Equity_Research_Model_v1", "risks": [ "Patent cliffs leading to revenue decline", "Increased competition in immunology market", "Regulatory setbacks for pipeline drugs", "Economic downturn affecting drug sales" ], "ticker": "ABBV", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady execution on current guidance.", "target_price": 213 }, "bear": { "prob": 0.3, "notes": "Slower drug adoption and multiple compression.", "target_price": 180 }, "bull": { "prob": 0.2, "notes": "Faster pipeline uptake and margin expansion.", "target_price": 240 } }, "confidence": 0.6, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.04, "terminal_multiple": 15, "ebit_margin_target": 0.25 }, "key_drivers": [ { "driver": "Humira biosimilar competition", "impact": "HIGH", "direction": "NEG" }, { "driver": "Skyrizi and Rinvoq growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Cost management and margin stability", "impact": "MED", "direction": "POS" }, { "driver": "Debt reduction efforts", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory approvals for new drugs", "impact": "HIGH", "direction": "POS" }, { "driver": "Healthcare policy changes", "impact": "MED", "direction": "NEG" }, { "driver": "Currency fluctuations", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Used forward earnings estimate with PE multiple based on snapshot forward PE. Recommendation based on modest upside and mixed evidence. Not investment advice.", "current_price": 211.59, "recommendation": "HOLD", "thesis_bullets": [ "Stable revenue growth from new immunology drugs.", "High debt load constrains financial flexibility.", "Dividend yield provides income support.", "Patent expirations pose ongoing risks.", "Valuation appears fair relative to peers." ], "target_price_6m": 212, "target_price_12m": 213 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 365, "createdAt": "2026-04-09T05:06:13.380Z", "usage": { "inputTokens": 2107, "outputTokens": 3089, "costUsd": 0.001887 } }, { "id": "cmnr0l2bx01kcp658kqs5mmkr", "runId": "cmnr0l2bq01k4p658meg8jxua", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"ABBV_Equity_Model_v1\",\n \"as_of\": \"2026-04-08T20:02:43.000Z\",\n \"ticker\": \"ABBV\",\n \"currency\": \"USD\",\n \"current_price\": 211.59,\n \"target_price_6m\": 222.0,\n \"target_price_12m\": 235.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.8,\n \"thesis_bullets\": [\n \"Skyrizi and Rinvoq are successfully offsetting Humira biosimilar erosion.\",\n \"Strong FCF generation of $17.7B supports a secure 2.9% dividend yield.\",\n \"Recent acquisitions in neuroscience and oncology bolster the long-term pipeline.\",\n \"Forward P/E of 15.6x is attractive relative to the return to top-line growth.\",\n \"High debt load of $67B remains a headwind for aggressive share repurchases.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Skyrizi and Rinvoq sales growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Humira biosimilar market share erosion\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Aesthetics (Botox) volume recovery\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Neuroscience portfolio expansion\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Debt reduction progress\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Pipeline clinical trial readouts\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"M&A integration costs\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Faster-than-expected Humira revenue decline due to aggressive biosimilar pricing.\",\n \"Regulatory setbacks or clinical trial failures in the oncology pipeline.\",\n \"Macroeconomic pressures impacting discretionary aesthetics (Botox) spending.\",\n \"High leverage limits capital allocation flexibility.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.35,\n \"wacc\": 0.075,\n \"terminal_multiple\": 14.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 180.0,\n \"prob\": 0.2,\n \"notes\": \"Humira erodes faster than expected and aesthetics growth stalls.\"\n },\n \"base\": {\n \"target_price\": 235.0,\n \"prob\": 0.6,\n \"notes\": \"Skyrizi and Rinvoq meet targets, driving mid-single-digit revenue growth.\"\n },\n \"bull\": {\n \"target_price\": 270.0,\n \"prob\": 0.2,\n \"notes\": \"Pipeline assets outperform and margins expand faster than anticipated.\"\n }\n },\n \"method_notes\": \"Valuation based on a 10-year DCF and 15.5x forward P/E multiple. The 11% upside supports a BUY rating. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:02:43.000Z", "model": "ABBV_Equity_Model_v1", "risks": [ "Faster-than-expected Humira revenue decline due to aggressive biosimilar pricing.", "Regulatory setbacks or clinical trial failures in the oncology pipeline.", "Macroeconomic pressures impacting discretionary aesthetics (Botox) spending.", "High leverage limits capital allocation flexibility." ], "ticker": "ABBV", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Skyrizi and Rinvoq meet targets, driving mid-single-digit revenue growth.", "target_price": 235 }, "bear": { "prob": 0.2, "notes": "Humira erodes faster than expected and aesthetics growth stalls.", "target_price": 180 }, "bull": { "prob": 0.2, "notes": "Pipeline assets outperform and margins expand faster than anticipated.", "target_price": 270 } }, "confidence": 0.8, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.05, "terminal_multiple": 14, "ebit_margin_target": 0.35 }, "key_drivers": [ { "driver": "Skyrizi and Rinvoq sales growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Humira biosimilar market share erosion", "impact": "HIGH", "direction": "NEG" }, { "driver": "Aesthetics (Botox) volume recovery", "impact": "MED", "direction": "POS" }, { "driver": "Neuroscience portfolio expansion", "impact": "MED", "direction": "POS" }, { "driver": "Debt reduction progress", "impact": "MED", "direction": "POS" }, { "driver": "Pipeline clinical trial readouts", "impact": "HIGH", "direction": "POS" }, { "driver": "M&A integration costs", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Valuation based on a 10-year DCF and 15.5x forward P/E multiple. The 11% upside supports a BUY rating. Not investment advice.", "current_price": 211.59, "recommendation": "BUY", "thesis_bullets": [ "Skyrizi and Rinvoq are successfully offsetting Humira biosimilar erosion.", "Strong FCF generation of $17.7B supports a secure 2.9% dividend yield.", "Recent acquisitions in neuroscience and oncology bolster the long-term pipeline.", "Forward P/E of 15.6x is attractive relative to the return to top-line growth.", "High debt load of $67B remains a headwind for aggressive share repurchases." ], "target_price_6m": 222, "target_price_12m": 235 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 22663, "createdAt": "2026-04-09T05:06:13.380Z", "usage": { "inputTokens": 2479, "outputTokens": 864, "costUsd": 0.015326 } }, { "id": "cmnr0l2bx01kap658infdxud4", "runId": "cmnr0l2bq01k4p658meg8jxua", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation v2\",\"as_of\":\"2026-04-08T20:02:43.000Z\",\"ticker\":\"ABBV\",\"currency\":\"USD\",\"current_price\":211.59,\"target_price_6m\":220,\"target_price_12m\":224,\"recommendation\":\"HOLD\",\"confidence\":0.66,\"thesis_bullets\":[\"Skyrizi and Rinvoq growth should offset most Humira erosion.\",\"Strong FCF supports dividends, debt reduction, and pipeline investment.\",\"Forward PE is reasonable, but leverage limits multiple expansion.\",\"Aesthetics and neuroscience diversify revenue but add execution risk.\",\"Shares appear near fair value after recent rerating.\"],\"key_drivers\":[{\"driver\":\"Skyrizi/Rinvoq growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Humira erosion normalization\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Aesthetics demand recovery\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Neuroscience franchise growth\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Debt paydown\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Drug pricing policy pressure\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Pipeline and patent outcomes\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Margin normalization\",\"impact\":\"MED\",\"direction\":\"POS\"}],\"risks\":[\"Faster legacy-product erosion than expected.\",\"US pricing reform reduces realized pricing.\",\"Pipeline setbacks or safety issues.\",\"Aesthetics weakness from softer consumer spending.\",\"High debt limits capital allocation flexibility.\"],\"assumptions\":{\"revenue_cagr_3y\":0.058,\"ebit_margin_target\":0.31,\"wacc\":0.08,\"terminal_multiple\":14.5},\"scenarios\":{\"bear\":{\"target_price\":185,\"prob\":0.25,\"notes\":\"Pricing pressure and weaker launches compress margins and valuation.\"},\"base\":{\"target_price\":224,\"prob\":0.5,\"notes\":\"Immunology growth, stable cash flow, and modest deleveraging support fair value.\"},\"bull\":{\"target_price\":252,\"prob\":0.25,\"notes\":\"Faster franchise growth and better mix drive rerating.\"}},\"method_notes\":\"Blended 12M view using snapshot fundamentals, cash-flow resilience, forward earnings context, and a conservative terminal multiple. HOLD fits ~5.9% 12M upside with mixed evidence and notable leverage/policy risks. No sell-side targets used; not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:02:43.000Z", "model": "AI Model Recommendation v2", "risks": [ "Faster legacy-product erosion than expected.", "US pricing reform reduces realized pricing.", "Pipeline setbacks or safety issues.", "Aesthetics weakness from softer consumer spending.", "High debt limits capital allocation flexibility." ], "ticker": "ABBV", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Immunology growth, stable cash flow, and modest deleveraging support fair value.", "target_price": 224 }, "bear": { "prob": 0.25, "notes": "Pricing pressure and weaker launches compress margins and valuation.", "target_price": 185 }, "bull": { "prob": 0.25, "notes": "Faster franchise growth and better mix drive rerating.", "target_price": 252 } }, "confidence": 0.66, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.058, "terminal_multiple": 14.5, "ebit_margin_target": 0.31 }, "key_drivers": [ { "driver": "Skyrizi/Rinvoq growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Humira erosion normalization", "impact": "HIGH", "direction": "POS" }, { "driver": "Aesthetics demand recovery", "impact": "MED", "direction": "POS" }, { "driver": "Neuroscience franchise growth", "impact": "MED", "direction": "POS" }, { "driver": "Debt paydown", "impact": "MED", "direction": "POS" }, { "driver": "Drug pricing policy pressure", "impact": "HIGH", "direction": "NEG" }, { "driver": "Pipeline and patent outcomes", "impact": "HIGH", "direction": "NEG" }, { "driver": "Margin normalization", "impact": "MED", "direction": "POS" } ], "method_notes": "Blended 12M view using snapshot fundamentals, cash-flow resilience, forward earnings context, and a conservative terminal multiple. HOLD fits ~5.9% 12M upside with mixed evidence and notable leverage/policy risks. No sell-side targets used; not investment advice.", "current_price": 211.59, "recommendation": "HOLD", "thesis_bullets": [ "Skyrizi and Rinvoq growth should offset most Humira erosion.", "Strong FCF supports dividends, debt reduction, and pipeline investment.", "Forward PE is reasonable, but leverage limits multiple expansion.", "Aesthetics and neuroscience diversify revenue but add execution risk.", "Shares appear near fair value after recent rerating." ], "target_price_6m": 220, "target_price_12m": 224 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_04ed05b3d459a5ce0069d734d798a4819489f6cda55204c83f", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 31792, "createdAt": "2026-04-09T05:06:13.380Z", "usage": { "inputTokens": 2377, "outputTokens": 1847, "costUsd": 0.030018 } }, { "id": "cmnr0l2bx01kdp658jdsh3kol", "runId": "cmnr0l2bq01k4p658meg8jxua", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:02:43.000Z\",\n \"ticker\": \"ABBV\",\n \"currency\": \"USD\",\n \"current_price\": 211.59,\n \"target_price_6m\": 228,\n \"target_price_12m\": 245,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Skyrizi and Rinvoq drive strong immunology growth\",\n \"Forward PE of 15.7x attractive vs growth outlook\",\n \"Consistent FCF supports dividend and debt reduction\",\n \"Pipeline expansion in oncology and neuroscience\",\n \"Humira erosion largely priced in at current levels\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Skyrizi/Rinvoq adoption\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Humira biosimilar impact\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"New oncology launches\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Operating cash flow\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Acquisition-related debt\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Dividend yield growth\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Regulatory approvals\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Pipeline success rate\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Accelerated Humira revenue loss\",\n \"Clinical trial setbacks\",\n \"Biosimilar competition intensity\",\n \"High debt burden in rising rates\",\n \"Regulatory or litigation issues\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.08,\n \"ebit_margin_target\": 0.33,\n \"wacc\": 0.085,\n \"terminal_multiple\": 17\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 185,\n \"prob\": 0.3,\n \"notes\": \"Faster erosion and trial failures pressure valuation.\"\n },\n \"base\": {\n \"target_price\": 245,\n \"prob\": 0.5,\n \"notes\": \"Steady new product growth meets consensus.\"\n },\n \"bull\": {\n \"target_price\": 285,\n \"prob\": 0.2,\n \"notes\": \"Accelerated adoption and positive pipeline data.\"\n }\n },\n \"method_notes\": \"DCF using 8% 3Y revenue CAGR, 33% EBIT margin, 8.5% WACC and 17x terminal. 12M target implies ~16% upside consistent with BUY. Uses snapshot data only. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:02:43.000Z", "model": "AI Equity Research Model", "risks": [ "Accelerated Humira revenue loss", "Clinical trial setbacks", "Biosimilar competition intensity", "High debt burden in rising rates", "Regulatory or litigation issues" ], "ticker": "ABBV", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady new product growth meets consensus.", "target_price": 245 }, "bear": { "prob": 0.3, "notes": "Faster erosion and trial failures pressure valuation.", "target_price": 185 }, "bull": { "prob": 0.2, "notes": "Accelerated adoption and positive pipeline data.", "target_price": 285 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.08, "terminal_multiple": 17, "ebit_margin_target": 0.33 }, "key_drivers": [ { "driver": "Skyrizi/Rinvoq adoption", "impact": "HIGH", "direction": "POS" }, { "driver": "Humira biosimilar impact", "impact": "HIGH", "direction": "NEG" }, { "driver": "New oncology launches", "impact": "MED", "direction": "POS" }, { "driver": "Operating cash flow", "impact": "HIGH", "direction": "POS" }, { "driver": "Acquisition-related debt", "impact": "MED", "direction": "NEG" }, { "driver": "Dividend yield growth", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory approvals", "impact": "MED", "direction": "POS" }, { "driver": "Pipeline success rate", "impact": "MED", "direction": "POS" } ], "method_notes": "DCF using 8% 3Y revenue CAGR, 33% EBIT margin, 8.5% WACC and 17x terminal. 12M target implies ~16% upside consistent with BUY. Uses snapshot data only. Not investment advice.", "current_price": 211.59, "recommendation": "BUY", "thesis_bullets": [ "Skyrizi and Rinvoq drive strong immunology growth", "Forward PE of 15.7x attractive vs growth outlook", "Consistent FCF supports dividend and debt reduction", "Pipeline expansion in oncology and neuroscience", "Humira erosion largely priced in at current levels" ], "target_price_6m": 228, "target_price_12m": 245 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "7b8b0872-8b2f-9152-b87a-2a6ece21ec58", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 12426, "createdAt": "2026-04-09T05:06:13.380Z", "usage": { "inputTokens": 2717, "outputTokens": 2169, "costUsd": 0.040686 } } ] } }